Pediatric Dosing Changes Reflect Growth, Not Worsening: A Guide for PI Attorneys

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 8 min read

When a child plaintiff's medication doses increase over time, defense attorneys may argue the condition is worsening or that the child is being over-treated. In reality, pediatric medication dosing is weight-based, and dose increases in growing children typically reflect normal growth rather than clinical deterioration — a distinction PI attorneys must understand and communicate.

Pediatric Dosing Changes Reflect Growth, Not Worsening: A Guide for PI Attorneys

Pediatric medication dosing is fundamentally different from adult dosing because children's doses are calculated based on body weight (mg/kg) or body surface area (mg/m2). When a child plaintiff's gabapentin dose increases from 100mg to 200mg to 300mg over the course of a year, this progression may reflect nothing more than the child growing from 25kg to 35kg to 45kg — the dose is increasing because the child is getting bigger, not because the condition is getting worse. Defense attorneys who cite dose increases as evidence of worsening or over-treatment are misinterpreting a basic principle of pediatric pharmacology.

• Pediatric drug doses are calculated by body weight (mg/kg) and must increase as the child grows to maintain the same therapeutic effect
• Dose increases in children do not have the same clinical meaning as dose escalation in adults
• Defense attorneys frequently mischaracterize growth-appropriate dose adjustments as evidence of worsening condition or over-treatment
• LienScripts' pharmacist review identifies growth-based dosing adjustments and documents the clinical rationale
• As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, weight-based dosing is pediatric pharmacology 101, and attorneys need to be prepared to explain it clearly to adjusters and juries

Weight-Based Dosing: The Basics

Nearly all medications prescribed to children use weight-based dosing. The prescriber determines the appropriate dose per kilogram of body weight (or per body surface area for some medications) and calculates the total dose based on the child's current weight. As the child grows, the same mg/kg dose produces a higher total daily dose in milligrams.

For example, if gabapentin is prescribed at 10mg/kg/day for a 30kg child, the daily dose is 300mg. Six months later, if that child weighs 35kg, maintaining the same 10mg/kg/day produces a daily dose of 350mg. The prescriber has not escalated therapy — they have maintained the same weight-adjusted dose for a growing child.

This principle applies across virtually every medication class used in pediatric PI cases:

Anti-epileptics (gabapentin, pregabalin, levetiracetam) — commonly prescribed for post-traumatic seizure prophylaxis or neuropathic pain in children, with doses adjusted at each weight check.

Muscle relaxants — dosed by weight in pediatric patients, requiring upward adjustment as the child grows.

Anti-inflammatories — both prescription NSAIDs and corticosteroids use weight-based dosing in children.

Antidepressants and anxiolytics — when prescribed for post-traumatic anxiety or depression in pediatric patients, doses are weight-adjusted.

How Defense Attorneys Misuse Dose Increases

The defense argument typically follows this pattern: "The child's medication doses have increased three times in the past year. This escalating treatment proves the child's condition is worsening, or alternatively, that the child is being over-treated and the pharmacy lien is inflated."

This argument relies on the adjuster or jury not understanding pediatric pharmacology. In adult cases, a dose increase often does indicate that the current dose is insufficient — an important clinical signal. For a thorough discussion of adult dose escalation as severity evidence, see Dose Escalation Documents Injury Progression.

But in pediatric cases, the dose increase must be evaluated against the child's growth curve. If the mg/kg dose remained constant while the total milligram dose increased, there was no escalation — just growth adjustment. Only if the mg/kg dose itself increased should the change be characterized as a clinical escalation.

Building the Growth-Dose Timeline

The most effective way to present pediatric dosing in a demand package or at trial is a dual-axis timeline showing the child's weight growth curve alongside the medication dose curve. When these two curves track proportionally, it visually demonstrates that dose increases were growth-driven, not condition-driven.

LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages. For pediatric cases, the MERIT documentation explicitly addresses weight-based dosing calculations, distinguishing between growth-appropriate adjustments and true clinical escalations.

When Dose Changes Do Indicate Worsening

Not every pediatric dose increase is growth-related. True clinical escalation occurs when the mg/kg dose itself increases, when new medications are added to the regimen, or when the child is switched to a different medication class. These changes have the same clinical significance as adult dose escalation and should be presented as evidence of ongoing or worsening injury.

The key is distinguishing between the two types of changes. A pharmacist review can calculate the mg/kg dose at each adjustment point and determine whether the change was growth-proportional or a true escalation. This distinction is critical for accurate case presentation.

Extended Treatment Duration in Pediatric Cases

Pediatric PI cases frequently involve longer treatment durations than adult cases because children may require medication management through their growth years. A medication that an adult might take for 12 months may need to be continued for years in a child, with regular dose adjustments. This extended duration — combined with regular dose increases for growth — creates a medication timeline that looks extensive on paper but reflects appropriate pediatric management.

For additional context on how medication complexity translates to damages, see Polypharmacy Burden as a Damages Element.

Practical Takeaway

When representing a pediatric PI plaintiff, attorneys should obtain the child's growth records alongside the medication history, have a pharmacist calculate the mg/kg dose at each adjustment point, and present any dose increases in the context of the child's growth. This prevents the defense from mischaracterizing normal growth adjustments as evidence of worsening or over-treatment.

Contact LienScripts to discuss how pharmacist review of pediatric medication management supports your case documentation.